Myopia represents one of the greatest challenges in contemporary ophthalmology, and the primary goal of its management is currently not only refractive correction but, more importantly, slowing disease progression and reducing the risk of developing high myopia. In recent years, therapeutic strategies have evolved from single interventions toward a comprehensive, personalized approach incorporating pharmacological treatment, advanced optical technologies, and modification of environmental risk factors. Atropine, particularly in low concentrations, remains one of the most extensively studied and evidence-based methods for myopia control; however, the rapid development of optical technologies has enabled the introduction of new solutions, including H.A.L.T., D.I.M.S., DOT, and C.A.R.E. spectacle lenses, which utilize controlled myopic defocus. Increasing attention has also been directed toward innovative light-based approaches, including repeated low-level red light therapy (RLRL) and digital photobiomodulation, although further studies are required to establish their long-term safety and efficacy. Combination therapy, integrating different mechanisms of action, represents another important direction of development, particularly in children with rapidly progressive myopia. The future of myopia control will rely on individualized treatment strategies that consider each patient's risk profile, rate of axial elongation, and optimal selection of therapeutic interventions.